Patents Assigned to NanoCruise Pharmaceutical Ltd.
  • Patent number: 11673966
    Abstract: The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and show the same specificity as the parental antibody.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 13, 2023
    Assignees: NanoCruise Pharmaceutical Ltd., Board of Regents of The University of Texas System
    Inventors: Dapeng Zhou, Patrick Hwu